Whole blood omega-3 fatty acid concentrations are inversely associated with blood pressure in young, healthy adults by Filipovic, Mark G et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Whole blood omega-3 fatty acid concentrations are inversely associated with
blood pressure in young, healthy adults
Filipovic, Mark G ; Aeschbacher, Stefanie ; Reiner, Martin F ; Stivala, Simona ; Gobbato, Sara ;
Bonetti, Nicole ; Risch, Martin ; Risch, Lorenz ; Camici, Giovanni G ; Luescher, Thomas F ; von
Schacky, Clemens ; Conen, David ; Beer, Juerg H
Abstract: BACKGROUND Omega-3 fatty acids (n - 3 FA) may have blood pressure (BP)-lowering effects
in untreated hypertensive and elderly patients. The effect of n - 3 FA on BP in young, healthy adults
remains unknown. The Omega-3 Index reliably reflects an individuals’ omega-3 status. We hypothesized
that the Omega-3 Index is inversely associated with BP levels in young healthy adults. METHODS The
current study (n = 2036) is a cross-sectional study investigating the baseline characteristics of a cohort,
which includes healthy adults, age 25-41 years. Individuals with cardiovascular disease, known diabetes or
a BMI higher than 35 kg/m were excluded. The Omega-3 Index was determined in whole blood using gas
chromatography. Association with office and 24-h BP was assessed using multivariable linear regression
models adjusted for potential confounders. RESULTS Median Omega-3 Index was 4.58% (interquartile
range 4.08; 5.25). Compared with individuals in the lowest Omega-3 Index quartile, individuals in the
highest had a SBP and DBP that was 4 and 2 mmHg lower, respectively (P < 0.01). A significant linear
inverse relationship of the Omega-3 Index with 24-h and office BP was observed. Per 1-U increase in
log-transformed Omega-3 Index the lowering in BP (given as multivariable adjusted ￿ coefficients; 95%
confidence interval) was -2.67 mmHg (-4.83; -0.51; P = 0.02) and -2.30 mmHg (-3.92; -0.68; P = 0.005) for
24-h SBP and DBP, respectively. CONCLUSION A higher Omega-3 Index is associated with statistically
significant, clinically relevant lower SBP and DBP levels in normotensive young and healthy individuals.
Diets rich in n - 3 FA may be a strategy for primary prevention of hypertension.
DOI: https://doi.org/10.1097/HJH.0000000000001728
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-169393
Journal Article
Published Version
Originally published at:
Filipovic, Mark G; Aeschbacher, Stefanie; Reiner, Martin F; Stivala, Simona; Gobbato, Sara; Bonetti,
Nicole; Risch, Martin; Risch, Lorenz; Camici, Giovanni G; Luescher, Thomas F; von Schacky, Clemens;
Conen, David; Beer, Juerg H (2018). Whole blood omega-3 fatty acid concentrations are inversely
associated with blood pressure in young, healthy adults. Journal of Hypertension, 36(7):1548-1554.
DOI: https://doi.org/10.1097/HJH.0000000000001728
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Whole blood omega-3 fatty acid concentrations are
inversely associatedwithblood pressure in young,
healthy adults
Mark G. Filipovica,b, Stefanie Aeschbacherc, Martin F. Reinera,b, Simona Stivalab, Sara Gobbatob,
Nicole Bonettib, Martin Rischd,e, Lorenz Rischd,f,g, Giovanni G. Camicib, Thomas F. Luescherh,
Clemens von Schackyi, David Conenc,j, and Juerg H. Beera,b
Background: Omega-3 fatty acids (n3 FA) may have
blood pressure (BP)-lowering effects in untreated
hypertensive and elderly patients. The effect of n 3 FA
on BP in young, healthy adults remains unknown. The
Omega-3 Index reliably reflects an individuals’ omega-3
status. We hypothesized that the Omega-3 Index is
inversely associated with BP levels in young healthy
adults.
Methods: The current study (n¼2036) is a cross-sectional
study investigating the baseline characteristics of a cohort,
which includes healthy adults, age 25–41 years. Individuals
with cardiovascular disease, known diabetes or a BMI
higher than 35 kg/m2 were excluded. The Omega-3 Index
was determined in whole blood using gas
chromatography. Association with office and 24-h BP was
assessed using multivariable linear regression models
adjusted for potential confounders.
Results: Median Omega-3 Index was 4.58% (interquartile
range 4.08; 5.25). Compared with individuals in the lowest
Omega-3 Index quartile, individuals in the highest had a
SBP and DBP that was 4 and 2mmHg lower, respectively
(P<0.01). A significant linear inverse relationship of the
Omega-3 Index with 24-h and office BP was observed. Per
1-U increase in log-transformed Omega-3 Index the
lowering in BP (given as multivariable adjusted b
coefficients; 95% confidence interval) was 2.67mmHg
(4.83; 0.51; P¼ 0.02) and 2.30mmHg (3.92;
0.68; P¼0.005) for 24-h SBP and DBP, respectively.
Conclusion: A higher Omega-3 Index is associated with
statistically significant, clinically relevant lower SBP and DBP
levels in normotensive young and healthy individuals. Diets
rich in n3 FA may be a strategy for primary prevention
of hypertension.
Keywords: blood pressure, hypertension, nutrition,
omega-3 fatty acids, population, prevention
Abbreviations: ALA, alpha-linolenic acid; BP, blood
pressure; DHA, docosahexaenoic acid; EPA,
eicosapentaenoic acid; n3 PUFA, omega-3
polyunsaturated fatty acid
INTRODUCTION
H
ypertension is one of the most prevalent health
conditions [1] affecting over 1 billion people
worldwide [2] and a leading cause of heart disease,
stroke and premature death [3]. Despite important preven-
tive efforts, incidence and prevalence of hypertension are
not only rising in elderly people [4] but also in younger and
otherwise healthy individuals – even in athletes [5]. Hence,
simple, well tolerated and cost-effective strategies to pre-
vent hypertension at an early stage are needed.
Omega-3 polyunsaturated fatty acids (n 3 PUFAs) con-
sist of the fish-derived fatty acids (FAs) eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) as well as the
plant-derived alpha-linolenic acid (ALA). Although their
role in hypertension is still subject to an intense and
ongoing scientific debate, they have been shown to have
multiple beneficial effects in cardiovascular disease [6]. Of
note, they have anti-inflammatory [7] as well as antithrom-
botic [8] activity, they improve endothelial dysfunction [9]
and positively influence resting heart rate (HR), HR vari-
ability [10,11], heart rhythm [12], cardiac remodeling [13]
and cardiac ion channel functions [14].
Concerning their antihypertensive properties, n 3
PUFAs were reported to directly modulate murine ion
channel functions in blood vessels, leading to
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vasodilatation [15]. In humans, higher red blood cell mem-
brane omega-3 content was associated with lower brachial
artery diameter (an independent predictor of cardiovascu-
lar events) and improved vasodilatory function [16]. Over-
all, omega-3 FAs were shown to reduce pulse wave velocity
and improve arterial compliance in humans [17]. Corre-
spondingly, three meta-analyses show that n 3 PUFA
administration reduces blood pressure (BP) in untreated
hypertensive patients, when supplemented with high dos-
ages of at least 3–4 g/day, with almost no or only very little
effect in normotensive individuals [18–20].
Few data are available on the effects of physiologic
nutritional n 3 on BP in healthy individuals, in whom
prevention measures could be implemented. From an
observational point of view, in the subcohort of 2038
normotensive adults without antihypertensive medication,
the observational INTERMAP study reported an inverse
relationship of total dietary n 3 PUFA consumption with
BP, resulting in an estimated difference of1.01 mmHg SBP
and 0.98 mmHg DBP with two SDs higher dietary n 3
PUFA intake [21]. However, n 3 PUFA intake was esti-
mated by nutritional assessments, which are known to be
unprecise [22]. Also, the study lacked ambulatory 24-h BP
measurements [21], which are better predictors of cardio-
vascular disease events [23–25] than office BP. Further, the
investigated subgroup included individuals already suffer-
ing from cardiovascular disease.
Therefore, aim of our study was to assess the association
of whole blood n 3 PUFA levels (given as the Omega-3
Index) with BP in a large population-based sample of
young and healthy adults.
METHODS
Study population
All participants of the current study are also part of the GAPP
study(genetic andphenotypicdeterminantsofbloodpressure
and other cardiovascular risk factors), a large population-
based cohort, which investigates the determinants of BP
and other cardiovascular risk factors in young and healthy
adults [26]. For this study, cross-sectional data from the base-
line measurements were analyzed. Briefly, the cohort is com-
posed of a representative population of 2170 healthy adults
aged 25–41 with residence in the Principality of Liechtenstein.
All inhabitants in the given age range were invited to partici-
pate in this study. Patients were screened and enrolled from
2010 to 2013. Main exclusion criteria include established
cardiovascular disease, chronic kidney disease, a BMI higher
than 35kg/m2, obstructive sleep apnea, daily intake of non-
steroidal anti-inflammatory medication, diabetes and other
severe illnesses such as multiple sclerosis or cancer [26].
From a total of 2170 patients enrolled in the GAPP study,
we excluded participants with invalid 24-h BP measure-
ments as defined below (n¼ 90), missing conventional BP
measurements (n¼ 2), current BP-lowering treatment for
diagnosed hypertension (n¼ 34) and missing blood sam-
pling (n¼ 8), resulting in 2036 individuals for this analysis.
The study protocol was approved by the local ethics
committee (Cantonal Ethics Commission of Zurich, Zurich,
Switzerland). Informed written consent was obtained from
every individual participant.
Blood pressure measurement
Conventional office BP was obtained in a quiet environment
after at least 5minof rest from the sittingparticipantbyuseof a
validated oscillometric device (Microlife BP3AG1; Microlife
AG Swiss Corporation, Widnau, Switzerland) in all partici-
pants [26]. Three consecutive measurements were performed,
and themeanof the last two readingswasused for all analyses.
Ambulatory BP measurements were obtained by a fully
automatic, noninvasive device (BR-102 plus; Schiller AG,
Baar, Switzerland) which has been validated by international
protocols [27]. The device measured BP every 15min
between 0730 and 2200h, and every 30min in the remaining
time within 24h. Daytime and night-time BP was identified
with a diary, to be kept by all participants during the
measurement period. Recordings were repeated if possible
in individuals with less than 80% of valid BP measurements.
For this analysis, we included only participants with at least
10 valid awake and at least five valid asleep BP measure-
ments in accordance with other large BP-databases [28].
Blood sampling and whole blood fatty acid
composition
Venous whole blood samples were collected from every
participant at baseline after an overnight fast. Samples were
immediately stored at 80 8C [26], which has been proven to
have no altering effect on the n 3 levels measured [29].
Whole blood compositionwas analyzed according to the high
sensitivity-Omega-3 Index methodology, initially described
for erythrocyte samples [30], by the use of a validated correc-
tion factor applicable for whole blood aliquots [31]. FA
methyl esters were generated from whole blood by acid
transesterification and analyzedbygas chromatography using
a GC2010 Gas Chromatograph (Shimadzu, Duisburg,
Germany) equipped with a SP2560, 100-m column (Supelco,
Bellefonte, Pennsylvania, USA) hydrogen as carrier gas. FAs
were identified by comparison with a standard mixture of FAs
characteristic of erythrocytes. Results are given as relative
amounts of EPA (C20 : 5n3) and DHA (C22 : 6n3), expressed
as a percentage of a total of 26 identified FAs, referred to as
Omega-3 Index.Wherementioned,ALA (C18 : 3n3) is givenas
percentage of a total of 26 identified FAs. The coefficient of
variation for FA levels was 5%. Analyses were quality con-
trolled according to DIN ISO 15189.
Assessment of other biomarkers
Creatinine and high-sensitivity C-reactive protein (hs-CRP)
were assayed from fresh samples immediately after blood
draw on a Roche Cobas (F. Hoffmann-La Roche, Basel,
Switzerland). Glycated hemoglobin A1c (HbA1c) was mea-
sured using HPLC. Estimated glomerular filtration rate
(eGFR) was calculated using the creatinine-based chronic
kidney disease epidemiology collaboration formula [32].
Other study variables
For all participants, a detailed assessment of personal,medical,
lifestyle and nutritional factors was performed. Smoking status
was self-assessed and categorized into current, past and never
smokers.Moderateandvigorousphysical activitywasassessed
using the validated international physical activity question-
naire [33]. Regular physical activity was defined as moderate or
vigorous physical activity of at least 75 or 150min/week,
n – 3 fatty acids and blood pressure in young and healthy adults
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respectively. Alcohol consumption and frequency of fruit,
vegetable and fish consumption were obtained with the Swiss
health survey questionnaire from 2007. Healthy diet was
defined as a fruit and vegetable consumption of at least five
servings per day. Highest educational status was reported.
Weight and height were measured in a standardized way. BMI
was calculated by dividing weight in kg by height in m2.
Statistical analysis
Data were tested against a predefined hypothesis, assuming
an inverse association of Omega-3 Index with BP indices.
Baseline characteristics were presented overall as well as
stratified according to quartiles of Omega-3 Index. Distribu-
tion of continuous variables was checked using visual inspec-
tion of the histogram, skewness and kurtosis. Continuous data
are presented as mean SD or median [interquartile range
(IQR)], depending on the distribution. Categorical data were
shown as numbers (percentages). Group comparisons across
quartileswere performed using analysis of variance, Kruskal–
Wallis tests or chi-square tests, as appropriate.
To assess the relationship ofn 3 PUFAs withBP, different
multivariable linear regressionmodelswere constructedusing
BP variables as the outcomevariable.Weusedquartiles of FAs
to assess the shape of the association with BP variables. P
values for trend were calculated using quartile-specific
medians. Afterwards continuous FA variables were included
to the model to assessb-coefficients [95% confidence intervals
(CIs)] per 1-U increase in FA. Due to the distribution of the
variables, levels of FAs were log-transformed for all analyses.
In addition, relationships between specific n 3 PUFAs
(DHA, EPA and ALA) and BP indices were calculated from
a hypothesis generating perspective.
The first model was adjusted for age and sex. In a second
model, the associations were additionally adjusted for BMI,
smoking status, HbA1c, educational status, fruit and vegeta-
ble consumption, alcohol consumption, physical activity,
eGFR and hs-CRP. A prespecified subgroup analysis was
performed using multivariable adjusted regression analysis
stratified by sex. A multiplicative interaction term was
included to the unstratified model to evaluate differences
among both strata.
Themultivariable adjusted regressionmodelwas adjusted
for age, sex, educational status, alcohol consumption, hs-
CRP and eGFR.
All statistical analyses were performed using SAS version
9.4 (SAS Institute Inc, Cary, North Carolina, USA), and a
value of P value less than 0.05 was prespecified to indicate
statistical significance.
RESULTS
Study population
Baseline characteristics for the whole population and
stratified by quartiles of the Omega-3 Index are shown in
TABLE 1. Baseline characteristics across Omega-3 Index quartiles
All, n¼2036 Quartile 1, n¼508 Quartile 2, n¼511 Quartile 3, n¼508 Quartile 4, n¼509 P value
Omega-3 Index range (%) 2.43–4.06 4.08–4.58 4.59–5.25 5.26–9.26
Omega-3 Index (%) 4.58 (4.08; 5.25) 3.76 (3.54; 3.94) 4.32 (4.19; 4.47) 4.89 (4.71; 5.04) 5.80 (5.49; 6.37) –
Docosahexaenoic acid (%) 3.09 (2.63; 3.62) 2.38 (2.18; 2.55) 2.87 (2.73; 3.02) 3.34 (3.17; 3.50) 4.02 (3.78; 4.42) –
Eicosapentaenoic acid (%) 0.61 (0.49; 0.78) 0.50 (0.41; 0.60) 0.57 (0.47; 0.67) 0.64 (0.52; 0.77) 0.83 (0.68; 1.06) –
Alpha-linolenic acid (%) 0.23 (0.18; 0.29) 0.22 (0.17; 0.28) 0.23 (0.18; 0.28) 0.23 (0.19; 0.29) 0.24 (0.19; 0.30) –
Age (years) 36.8 (31.2; 40.3) 36 (30; 40) 36 (31; 40) 37 (31; 40) 37 (33; 40) 0.22
Male sex (%) 950 (46.7) 280 (55.1) 245 (48.0) 228 (44.9) 197 (38.7) <0.0001
BMI (kg/m2) 24.53.7 25.14.0 24.73.7 24.43.5 23.73.5 <0.0001
Smoking (%) <0.0001
Current 477 (22.0) 165 (32.5) 131 (25.7) 96 (18.9) 55 (10.8)
Past 478 (23.5) 114 (22.5) 117 (22.9) 123 (24.3) 124 (24.4)
Never 1108 (54.5) 228 (45.0) 262 (51.4) 288 (56.8) 330 (64.8)
Education (%) <0.0001
Basic 155 (7.7) 45 (9.0) 37 (7.3) 29 (5.8) 44 (8.7)
Middle 1091 (54.2) 317 (63.7) 289 (57.2) 274 (54.6) 211 (41.6)
High 766 (38.1) 136 (27.3) 179 (35.5) 199 (39.6) 252 (49.7)
LDL (mmol/l) 2.980.85 3.050.90 2.980.83 2.970.83 2.920.85 0.12
HDL (mmol/l) 1.540.42 1.440.41 1.510.40 1.560.43 1.630.42 <0.0001
Cholesterol (mmol/l) 4.81 (4.29; 5.48) 4.85 (4.34; 5.51) 4.82 (4.24; 5.40) 4.85 (4.29; 5.56) 4.73 (4.24; 5.40) 0.26
Triglycerides (mmol/l) 0.84 (0.60; 1.20) 0.98 (0.65; 1.46) 0.87 (0.62; 1.22) 0.83 (0.60; 1.14) 0.75 (0.57; 1.02) <0.0001
Glycated hemoglobin A1c (%) 5.4 (5.2; 5.6) 5.5 (5.2; 5.7) 5.4 (5.2; 5.6) 5.4 (5.2; 5.6) 5.4 (5.2; 5.6) 0.31
Regular physical activity (%) 1635 (80.3) 408 (80.3) 414 (81.0) 404 (79.5) 409 (80.4) 0.95
Fish consumption 2 servings/week (%) 264 (13.0) 29 (5.7) 31 (6.1) 67 (13.2) 137 (27.0) <0.0001
Fruit/vegetable consumption (%) 393 (19.3) 74 (14.6) 90 (17.6) 96 (18.9) 133 (26.1) <0.0001
hs-CRP (mg/l) 0.90 (0.50; 1.90) 0.9 (0.5; 1.7) 0.9 (0.5; 2.1) 1.0 (0.5; 2.0) 0.8 (0.4; 1.7) 0.05
Estimated glomerular filtration rate (ml/min) 112 (103; 118) 113 (106; 119) 112 (103; 118) 111 (103; 118) 112 (101; 118) 0.06
Blood pressure
Systolic office BP (mmHg) 12013 12213 12112 11912 11813 <0.0001
Diastolic office BP (mmHg) 789 799 798 789 779 0.0003
24-h SBP (mmHg) 12311 12512 12311 12311 12111 <0.0001
24-h DBP (mmHg) 788 799 797 788 778 0.0002
Systolic daytime BP (mmHg) 12712 12913 12711 12611 12512 <0.0001
Diastolic daytime BP (mmHg) 828 839 827 818 818 0.0005
Systolic night-time BP (mmHg) 10911 11112 10910.9 10911 10711 <0.0001
Diastolic night-time BP (mmHg) 668 678 678 668 668 0.0006
n¼2036; data are means SD, medians (interquartile range) or numbers (percentages). Regular physical activity¼moderate or vigorous physical activity at least 150 or 75min/week.
Fruit and vegetable consumption¼ fruit and vegetable consumption at least five servings per day. BP, blood pressure; hs-CRP, high-sensitivity C-reactive protein.
P value was calculated using analysis of variance, Kruskal–Wallis test or chi-square test, as appropriate, to compare the respective values across the quartiles.
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Table 1. Median age of our population was 37 years (IQR
32; 40), and 53% were women. Median Omega-3 Index was
4.58% (IQR 4.08; 5.25). Mean systolic and diastolic office BP
was 120 13 and 78 9mmHg, respectively.
A higher Omega-3 Index was associated with a higher
prevalence of women, a lower BMI and less smoking (P
value for all<0.0001). In addition, individuals with a higher
Omega-3 Index had higher HDL levels (P< 0.0001), lower
triglycerides (P< 0.0001) and consumed significantly more
fruits and vegetables (P< 0.0001) as well as fish
(P< 0.0001). Groups with a higher Omega-3 Index also
had a higher educational status (P< 0.0001). With increas-
ing Omega-3 Index, all BP indices decreased linearly (Table
1). Compared with individuals in the lowest Omega-3 Index
quartile, those in the highest had a 4 and 2-mmHg lower 24-
h SBP and DBP, respectively (P< 0.01).
Relationship between omega-3 fatty acids and
blood pressure
On a continuous scale, systolic and diastolic office and 24-h
BP remained inversely associated with the Omega-3 Index
after correction for a multitude of potential confounders.
Results of multivariable regression models for the relation-
ship of Omega-3 Index and individual FAs with BP are
shown in Table 2. Per 1-U increase in log-transformed
Omega-3 Index multivariable adjusted b coefficients
(95% CI) were 2.66 (4.83; 0.51; P¼ 0.02) for 24-h
SBP, 2.30 (3.92; 0.68; P¼ 0.005) for 24-h DBP,
2.81 (5.22; 0.40; P¼ 0.02) for systolic office and
1.86 (3.68; 0.04; P¼ 0.05) for diastolic office BP. A
subgroup analysis stratified by sex showed no significant
differences (Table S1, http://links.lww.com/HJH/A919).
DHA was inversely associated with virtually all BP indi-
ces except for systolic night-time and diastolic conventional
BP (Table 2). However, no significant results could be
found for the associations between BP and EPA or BP
and ALA (Table 2). The relationships of BP indices across
quartiles of FAs are presented in Tables S2–S5, http://
links.lww.com/HJH/A919.
DISCUSSION
In the current study, we found a linear inverse association
of n 3 PUFAs with SBP and DBP in young, healthy
individuals aged 25–41 years – no specific sex differences
being observed. Importantly, the results were consistent
throughout all measured indices, namely not only in-office
but also 24-h BP as a much more reliable assessment of true
BP levels [25], and after comprehensive adjustments.
Our findings support the hypothesis of BP-lowering
effects of n 3 PUFAs, as indicated in a variety of interven-
tion studies [34]. Even more importantly, our study specifi-
cally shows that, in a young and healthy population, whole
blood n 3 PUFAs are associated with lower BP. Signifi-
cantly, previous studies mainly administered large amounts
of more than 3-g n 3 PUFAs, which are largely impossible
to obtain through usual diets [35] and included mostly
hypertensive and middle-aged individuals [36]. Data on
cardiovascular effects of physiological, ‘every day’ dietary
n 3 FA consumption in healthy individuals have been
scarce [18,37]. Yet early, long-term and rather low-dose
dietary exposure to n 3 PUFAs may be particularly attrac-
tive as a well tolerated intervention to lower BP and prevent
the development of hypertension with little expected side
effects, if any [38].
In the current study population, we observed a signifi-
cantly higher prevalence of traditional cardiovascular risk
factors like age, male sex, higher BMI, smoking, lower
educational status and higher LDL and triglyceride profile
with lower Omega-3 Index [39]. However, after correcting
for these risk factors and a broad variety of other possible
confounders, the inverse association between the Omega-3
Index and all BP indices, except for isolated nocturnal 24-h
SBP, remained significant, attesting to the robustness and
independence of our findings.
TABLE 2. Relationship between fatty acids and blood pressure indices
Omega-3 Index Docosahexaenoic acid Eicosapentaenoic acid Alpha-linolenic acid
SBP 24-h Model 1 3.97 (6.11; 1.82), P< 0.001 3.71 (5.49; 1.92), P<0.0001 0.25 (1.41; 0.90), P¼0.66 0.21 (1.38; 0.97), P¼0.73
Model 2 2.67 (4.83; 0.51), P¼ 0.02 2.49 (4.28; 0.69), P¼0.007 0.25 (1.41; 0.91), P¼0.67 0.18 (0.98; 1.34), P¼0.76
DBP 24-h Model 1 3.31 (4.92; 1.70), P< 0.0001 2.75 (4.09; 1.41), P<0.0001 1.00 (1.86; 0.13), P¼0.02 0.18 (1.06; 0.71), P¼0.70
Model 2 2.30 (3.92; 0.68), P¼ 0.005 1.90 (3.25; 0.56), P¼0.006 0.76 (1.63; 0.11), P¼0.09 0.24 (0.62; 1.11), P¼0.58
SBP day Model 1 4.02 (6.25; 1.80), P< 0.0001 3.87 (5.72; 2.02), P<0.0001 0.07 (1.27; 1.13), P¼0.91 0.01 (1.24; 1.21), P¼0.98
Model 2 2.66 (4.91; 0.41), P¼ 0.02 2.57 (4.44; 0.70), P¼0.007 0.09 (1.29; 1.12), P¼0.89 0.37 (0.84; 1.57), P¼0.55
DBP day Model 1 3.38 (5.09; 1.66), P< 0.0001 2.84 (4.27; 1.41), P<0.0001 0.97 (1.89; 0.05), P¼0.04 0.10 (1.05; 0.84), P¼0.83
Model 2 2.22 (3.95; 0.49), P¼ 0.01 1.87 (3.31; 0.43), P¼0.01 0.70 (1.63; 0.23), P¼0.14 0.35 (0.58; 1.27), P¼0.46
SBP night Model 1 3.26 (5.56; 0.96), P¼ 0.005 2.69 (4.61; 0.78), P¼0.006 0.97 (2.20; 0.27), P¼0.12 0.64 (1.90; 0.62), P¼0.32
Model 2 2.02 (4.35; 0.31), P¼0.09 1.64 (3.58; 0.30), P¼0.10 0.68 (1.93; 0.57), P¼0.29 0.23 (1.47; 1.01), P¼0.72
DBP night Model 1 2.70 (4.36; 1.04), P¼ 0.001 2.12 (3.50; 0.74), P¼0.003 1.07 (1.96; 0.18), P¼0.02 0.28 (1.19; 0.63), P¼0.55
Model 2 2.14 (3.84; 0.45), P¼ 0.01 1.71 (3.11; 0.30), P¼0.02 0.84 (1.74; 0.07), P¼0.07 0.04 (0.87; 0.94), P¼0.93
Systolic
conventional BP
Model 1 3.98 (6.38; 1.58), P¼ 0.001 3.47 (5.47; 1.48), P¼0.0007 0.81 (2.10; 0.48), P¼0.22 0.63 (0.69; 1.94), P¼0.35
Model 2 2.81 (5.22; 0.40), P¼ 0.02 2.46 (4.46; 0.46), P¼0.02 0.62 (1.91; 0.67), P¼0.34 0.98 (0.31; 2.26), P¼0.14
Diastolic
conventional BP
Model 1 2.78 (4.58; 0.98), P¼ 0.003 2.12 (3.63; 0.62), P¼0.006 1.07 (2.04; 0.10), P¼0.03 0.26 (0.72; 1.25), P¼0.60
Model 2 1.86 (3.68; 0.04), P¼ 0.05 1.41 (2.93; 0.11), P¼0.07 0.72 (1.70; 0.25), P¼0.15 0.67 (0.31; 1.64), P¼0.18
n¼2036; data are b-coefficients (95% confidence intervals). Fatty acid variables were used as a log-transformed variable. Model 1 was adjusted for age and sex; Model 2 was
additionally adjusted for BMI, smoking status, glycated hemoglobin A1c, educational status, fruit/vegetable consumption, physical activity, estimated glomerular filtration rate, high-
sensitivity C-reactive protein, alcohol consumption. BP, blood pressure.
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Of note, our population had a median Omega-3 Index of
4.6% and was therefore highly comparable with data and
recently published studies from the United States, with an
average Omega-3 Index of 4–5% [40]. Significantly, the
Omega-3 Index in Japan, a country with one of the highest
fish consumption, highest life expectancies and lowest rates
of coronary artery disease, is between 9 and 11% [41,42]. An
Omega-3 Index more than 8% has been proposed to
provide for optimal cardioprotection [31], whereas no ceil-
ing effect was observed for major coronary events in the
large JELIS study (n¼ 18 645) [43], and a significant raise in
Omega-3 Index is achievable through increased dietary
intake and/or by long-term n 3 supplementation
[44,45]. This conforms with the findings in the present
population in which a statically relevant increase in fish
consumption across quartiles can be observed – but overall
regular fish consumption remains very low in all quartiles
and is thus probably responsible for the low median and
range of Omega-3 Index.
In consequence, there is a high likelihood that in future
long-term interventional studies, based on the observed
association between n 3 PUFAs and BP, early low-dose
dietary or n 3 PUFAs supplementation might lower BP
and/or prevent the onset of hypertension in healthy youn-
ger individuals at risk. Beyond that, the present data suggest
that in the measured range of our population, no specific
lower n 3 threshold exists. Indeed, n 3 PUFA is likely to
be a continuous beneficial variable, as the Omega-3 Index
is known to be an independent risk factor for cardiovascu-
lar disease [46]. Hence, even a low-dose dietary or phar-
macological intervention of longer duration should
be effective.
The association of n 3 PUFAs with lower BP may be
explained by a variety of direct antihypertensive as well as
secondary anti-inflammatory and antiatherosclerotic mech-
anisms [36]. A significant reduction of endothelial activa-
tion, inflammation and eventually atherogenesis has been
shown by our group in various experimental models [8,47].
Although statistically NS and with potential residual con-
founding, we observed lower levels of hs-CRP in the high
n 3 PUFA quartile, indicating that anti-inflammatory
mechanisms may at least play a role in BP modulation.
Further mechanisms for BP reduction by n 3 PUFA
include an interaction with the nitric oxide pathway, block-
ade of the angiotensin pathway and a reduction of vaso-
constrictor prostanoids [48]. A direct effect of n 3 PUFA
application was reported by Hoshi et al. [15] after intrave-
nous administration of a n 3 PUFA bolus, which in rats led
to a dose-dependent BP decrease through ion-channel-
mediated vasodilatation. Finally, two intervention studies
have shown a decrease in BP through Omega-3 Index
increase [49,50].
Individual subanalyses of EPA, DHA and ALA in our
study suggest that the observed association of n 3 PUFAs
with BP is mainly driven by DHA, which has also been
observed in a number of experimental and clinical trials
[51]. In line with this interpretation, a small randomized
controlled trial by Mori et al. [52] found that DHA, but not
EPA supplementation, resulted in BP reduction in over-
weight men. The precise mechanism and clinical signifi-
cance of this observation remains unknown. Possibly, the
BP-lowering effect of n 3 PUFAs is more chain length
dependent than other antiatherosclerotic properties which
we were able to induce with isolated ALA [8,47].
The strengths of our study include the definition and
homogeneity of our large and well characterized, truly
healthy population with easy access to preventive and
therapeutic medical services in Liechtenstein and careful
exclusion of any individuals with treated hypertension,
diabetes or any major illness, allowing to minimize con-
founding. In addition, thanks to the use of 24-h BP record-
ings, we were able to assess a variety of BP indices.
Importantly, our observation was consistent in both in-
office and 24-h BP. Also, the implementation of the
Omega-3 Index as a marker for n 3 PUFA intake provided
good comparability with other studies and a well estab-
lished measurement of n 3 PUFA levels with a reduced
biologic and analytic variability. Compared with plasma
phospholipid levels, which may differ up to a factor of 3.5
depending on sample, analyzing laboratory and method
used [53] or often unreliable nutritional questionnaires [22],
the Omega-3 Index is very robust to short-term changes of
n 3 PUFA intake and reliably reflects an individual’s long-
term omega-3 status and tissue omega-3 PUFA content [29].
Therefore, the Omega-3 Index has the potential to become
a cardiovascular risk factor as much as the HbA1c in people
with diabetes, which similarly takes advantage of the red
cell life span exposure of the past 120 days [29].
Limitations of our study include the cross-sectional
design preventing to infer causal relationship or to deter-
mine the directionality of the observed effects. Second,
despite extensive adjustment, we cannot exclude the pos-
sibility that the association between n 3 PUFA levels and
outcomes may be due to residual confounding – despite
excellent pathophysiological mechanistic evidence. Third,
the findings of our study are limited to the population
studied (white, young and healthy individuals) and the
nutritional habits, which are also influenced by geography
and culture. Fourth, none of the results were adjusted for
multiple testing, given a clear, predefined hypothesis and to
avoid potential overadjustment because of significant cor-
relations between individual FAs. Further, data on esti-
mated sodium intake from dietary questionnaires or
urinary excretion were not available, the inclusion of which
might have added to the exact definition of the observed
association. Lastly, we do not have data on the source of
n 3 PUFAs or the number of individuals taking supple-
ments. The latter is likely to be very low given the relatively
low levels of the n 3 concentrations measured and are
probably not of relevance to the association, with the
Omega-3 Index representing an active biologic analogue
(independent of data on the form and frequency of intake).
In conclusion, our study shows that even differences in
omega-3 levels achieved through standard nutrition are
associated with a significant and clinically relevant differ-
ence in BP among young and healthy adults. Thus, an n 3
FA rich diet might become a well tolerable strategy for
primary prevention of hypertension and its detrimental
consequences – provided these observations will be con-
firmed in future randomized controlled trials. Nevertheless,
given the increasing prevalence of hypertension with age, it
will be interesting and a great opportunity to observe the
Filipovic et al.
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development of this cohort prospectively, with respect to
the changes in the Omega-3 Index, the incidence of hyper-
tension and associated cardiovascular diseases.
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Reviewers’ Summary Evaluations
Reviewer 1
Whilst it is known that fish oil supplementation can lower
blood pressure, especially in establishedhypertension, this
study by Filipovic et al. highlights the relationship between
the omega-3 index, a reliable measure of omega-3 status,
and blood pressure in a young, predominantly normoten-
sive population. Although omega-3 intakes were not
assessed, the low levels of fish consumption are consistent
with the low omega-3 index range observed in this popu-
lation. The strength of the cross-sectional associations
highlights the importance of monitoring this robust bio-
marker of omega-3 status in individuals, particularly in
intervention trials where many factors including back-
ground intake can influence the efficacy of omega-3 sup-
plementation.
Reviewer 2
An inverse relation between blood levels of Omega-3
PUFA’s and blood pressure is found in a nonhypertensive,
young adult population. This may be entirely related to diet,
but alternate pathways should be explored to explain
the finding.
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